AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35641012
Drug: Behaviour change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour change physiotherapy intervention (6, 30 min weekly group-based exercise sessions preceded by a 30 min cognitive behaviour discussion group)
Trial: 35641012
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (6, 30 min weekly group-based exercise sessions)
Trial: 33093457
Drug: IRE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRE plus allogeneic γδ T-cell infusion (Group A)
Trial: 33093457
Drug: IRE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRE plus allogeneic γδ T-cell infusion (multiple courses)
Trial: 33093457
Drug: IRE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRE plus allogeneic γδ T-cell infusion (single course)
Trial: 33297719
Drug: Ulipristal Acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ulipristal Acetate (UPA) 5 mg/day
Trial: 32583431
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A (twice weekly bortezomib in one six-week cycle followed by eight five-week cycles of four times once weekly bortezomib with melphalan and prednisolone on days 1–4)
Trial: 32583431
Drug: Arm B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B (nine four-week cycles of three times once weekly bortezomib with melphalan and prednisolone on days 1–4)
Trial: 34146100
Drug: RSVPreF3 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVPreF3 vaccine (30/60/120 µg)
Trial: 33239409
Drug: Esaxerenone (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esaxerenone (1.25 mg/d titrated to 2.5 mg/d)
Trial: 32521250
Drug: TS-121 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-121 10 mg
Trial: 32521250
Drug: TS-121 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-121 50 mg
Trial: 32014520
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg followed by misoprostol 800 mcg buccally
Trial: 33203692
Drug: Genetic variants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic variants in the retinoic acid receptor alpha (RARA) gene
Trial: 33687734
Drug: Tongue cleaning
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongue cleaning with routine oral care
Trial: 33687734
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral care alone (Control)
Trial: 33118727
Drug: Bretschneider's HTK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bretschneider's HTK solution
Trial: 32527261
Drug: PopART standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PopART standard of care door‐to‐door HTS plus oral HIVST (33 clusters)
Trial: 33215948
Drug: Standard medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medication for acute BP
Trial: 33127947
Drug: L. reuteri
RxNorm normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. reuteri oil drops and ω‐3 PUFA capsules
Trial: 33127947
Drug: L. reuteri
RxNorm normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. reuteri and placebo regarding ω‐3 PUFA
Trial: 33127947
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules and placebo oil drops
Trial: 34438047
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (BFB + TDCS)
Trial: 35429046
Drug: Expert-match treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expert-match treatment
Trial: 35429046
Drug: Self-matching treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-matching treatment
Trial: 32730977
Drug: Bumetanide (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (1.0 mg twice daily for 91 days)
Trial: 32236116
Drug: One prandial
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One prandial insulin injection before breakfast or main meal with rapid-acting insulin
Trial: 32236116
Drug: One prandial
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One prandial insulin injection
Trial: 32250463
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg twice daily (Day 8) and once daily (Days 9–16) with a single oral 2.5 mg dose of esaxerenone
Trial: 32250463
Drug: Rifampicin 600
RxNorm normalized name: Rifampicin 600 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg once daily (Days 8–16) with a single oral 5 mg dose of esaxerenone
Trial: 33378776
Drug: Conventional colostomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional colostomy (CC)
Trial: 33337397
Drug: Conventional Physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Physiotherapy (40 minutes twice a day, 5 times a week for 4 weeks)
Trial: 33616561
Drug: Two-implant mandibular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-implant mandibular overdentures (IODs)
Trial: 34515552
Drug: Individualized oral
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized oral health education (OHE) via a behavioral and educational counseling approach
Trial: 32068603
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of conbercept (IVC) 7 days before vitrectomy (group A)
Trial: 32068603
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of conbercept (IVC) 14 days before vitrectomy (group B)
Trial: 32068603
Drug: No intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravitreal injection of conbercept (non-IVC, group C)
Trial: 35878047
Drug: Computerized Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized Cognitive Rehabilitation Therapy (CCRT) - 24 biweekly 90-min sessions
Trial: 32471973
Drug: Aprepitant (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (125 mg on the 1st day and 80 mg during the following days)
Trial: 36066520
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention including educational outreach, computerized clinical decision support on contrast volume and hemodynamic‐guided intravenous fluid targets, and audit and feedback.
Trial: 34600060
Drug: API tablets
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: API tablets at low and high compression
Trial: 34600060
Drug: API tablets
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: API tablets
Trial: 32413174
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (CST)
Trial: 37060024
Drug: Angiotensin-receptor blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-receptor blockers (ARBs)
Trial: 33662995
Drug: Homeopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic treatment for 6 months
Trial: 33662995
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no homeopathic treatment)
Trial: 35568571
Drug: 3-session motivational
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-session motivational enhancement therapy (MET)
Trial: 35568571
Drug: 8-session social
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-session social behaviour and network therapy (SBNT)
Trial: 33832806
Drug: Bilateral erector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral erector spinae plane block with 20 mL per side of 0.25% levobupivacaine (group E)
Trial: 33832806
Drug: Sham block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham block with 20 mL of normal saline (group C)
Trial: 34360267
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention consisting of education and feedback on reducing benzodiazepine prescriptions
Trial: 32442746
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy (MT) during the immobilisation period, in addition to conventional physiotherapy.
Trial: 36416166
Drug: Pedometer-based walking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pedometer-based walking program plus TheraBand resistance exercise (7,500 steps/day for 5 days/week, resistance exercise twice a week)
Trial: 36416166
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine daily activities)
Trial: 33347597
Drug: IUI‐CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IUI‐CC
Trial: 33603385
Drug: Digital medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital medicine system (DMS)
Trial: 34924999
Drug: Nalbuphine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.15 mg/kg combined with propofol
Trial: 34924999
Drug: Nalbuphine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.2 mg/kg combined with propofol
Trial: 33485959
Drug: BDP/FF/G (beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF/G (beclomethasone dipropionate, formoterol fumarate, glycopyrronium)
Trial: 35773027
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen concentrate (FC) 4 g
Trial: 33710111
Drug: Prolonged prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged prophylactic systemic antibiotics (PPSA) administered for the duration of the drain
Trial: 33710111
Drug: Non-prolonged prophylactic
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-prolonged prophylactic systemic antibiotics (non-PPSA) administered for 24 hours postoperatively
Trial: 34622731
Drug: Oral D-methionine
RxNorm normalized name: D-Methionine
DrugBank: D-Methionine (DB02893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral D-methionine (D-met)
Trial: 34960093
Drug: INV-MFGM (investigational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INV-MFGM (investigational cow's milk-based IF/100 kcal: 1.9 g protein, 1.2 mg iron, 25 mg ARA and whey protein-lipid concentrate, 5 g/L (source of bMFGM))
Trial: 34960093
Drug: Control (marketed,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (marketed, routine cow's milk-based IF/100 kcal: 2.1 g protein, 1.8 mg iron, 34 mg ARA)
Trial: 34001705
Drug: Control app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Control app allowing daily reporting of sexual behaviour and medication intake
Trial: 32552074
Drug: Short tablet
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short tablet training (Control)
Trial: 34118123
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of dexketoprofen
Trial: 34118123
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of paracetamol
Trial: 33816430
Drug: Seeking health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seeking health advice or treatment
Trial: 35123290
Drug: Dialectical behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behavior therapy (DBT) for 12 weeks
Trial: 33617699
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) - 10 weekly sessions
Trial: 36232205
Drug: Standard message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard message on oral rehydration solution
Trial: 34636752
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine (1.5 mg/kg bolus of 1% lidocaine after anesthesia induction followed by a continuous infusion of 2 mg/kg/h up to 1 h after surgery)
Trial: 34032710
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy plus adjuvant gemcitabine plus cisplatin
Trial: 34032710
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy plus adjuvant 5-fluorouracil plus cisplatin
Trial: 34130883
Drug: Moderna vaccine
RxNorm normalized name: Moderna COVID-19 Vaccine
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderna vaccine (1 dose)
Trial: 37072577
Drug: Glimepiride 4
RxNorm normalized name: glimepiride 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 4 mg/day
Trial: 34398956
Drug: LPV/r 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r 400 mg/100 mg twice daily + RBT 150 mg/day (Arm A)
Trial: 34398956
Drug: LPV/r 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r 800 mg/200 mg twice daily + RIF 600 mg/day (Arm B)
Trial: 34398956
Drug: LPV/r 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r 400 mg/100 mg twice daily + RAL 400 mg twice daily + RBT 150 mg/day (Arm C)
Trial: 32423396
Drug: Journal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Journal therapy counseling (3 in-person sessions and 3 telephone sessions)
Trial: 34773292
Drug: Thalidomide 25
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide 25 mg/d
Trial: 34773292
Drug: Thalidomide 50
RxNorm normalized name: thalidomide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide 50 mg/d
Trial: 32210157
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (reference group)
Trial: 35976944
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (1000 μg MK‐7/day)
Trial: 34735762
Drug: Subanesthetic IV
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subanesthetic IV ketamine (0.3 mg/kg)
Trial: 34735762
Drug: Caudal 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal 0.125% bupivacaine (1 ml/kg)
Trial: 34776421
Drug: Vibratory stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibratory stimulation during 2-week task-practice therapy
Trial: 34776421
Drug: No stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No stimulation (control group) during 2-week task-practice therapy
Trial: 37593838
Drug: Phentermine (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine (37.5 mg)
Trial: 35248274
Drug: Osteopathic Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic Treatment (4 treatments over 8 weeks)
Trial: 35248274
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (no osteopathic treatment)
Trial: 35012538
Drug: Regular dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dose group coaching (5 months)
Trial: 35012538
Drug: Extended dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended dose group coaching (5 months + 18 months one-on-one coaching)
Trial: 35012538
Drug: Regular dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dose group coaching with unstructured engagement of scientific advisors
Trial: 35012538
Drug: Regular dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dose group coaching with structured engagement of scientific advisors
Trial: 34402784
Drug: Solriamfetol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol (150 mg or 300 mg)
Trial: 34402784
Drug: Modafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (200 mg or 400 mg)
Trial: 33290635
Drug: Conventional symptomatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional symptomatic treatment (Miconaz oral gel, BBC oral spray)
Trial: 33290635
Drug: 3% chamomile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% chamomile topical oral gel
Trial: 33290635
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment + 3% chamomile topical oral gel
Trial: 36351174
Drug: No sodium
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No sodium bicarbonate infusion (control group)
Trial: 34073203
Drug: Hybrid model
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid model based on 3D structure of peptides; specific dosage and duration not mentioned.
Trial: 34073203
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro experiments with five randomly selected novel ACPs; specific dosage and duration not mentioned.
Trial: 32156842
Drug: Nano-curcumin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-curcumin (120 mg) for 12 weeks
Trial: 35972211
Drug: OCS (Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCS (Oral Corticosteroids)
Trial: 34332788
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg/Ω-3 fatty acids 4 g (UI-018)
Trial: 34332788
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg + placebo (control)
Trial: 33196567
Drug: Sequential procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sequential procedure (scleral-fixated IOL implantation followed by DSAEK)
Trial: 32861614
Drug: Interprofessional intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interprofessional intervention focusing on neuroleptics and potentially inadequate medications
Trial: 34755262
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (127 patients)
Trial: 34755262
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy (13 patients)
Trial: 32068426
Drug: SMT (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMT (standard manualized treatments)
Trial: 33606009
Drug: Azithromycin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (single 1-g dose)
Trial: 33457425
Drug: Metformin (≤1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (≤1000 mg/d) added to insulin for 24 weeks
Trial: 33402601
Drug: Drip intravenous
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drip intravenous administration of endostar (DE)
Trial: 33402601
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous administration of endostar (CE)
Trial: 34347883
Drug: Crenezumab (600–7,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenezumab (600–7,200 mg)
Trial: 34347883
Drug: Placebo (4–40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4–40 mL)
Trial: 34347883
Drug: Crenezumab (high-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenezumab (high-dose, high-concentration, high-volume)
Trial: 35978329
Drug: BI 764524
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 764524 (0.5, 1.0, or 2.5 mg) in the SRD part
Trial: 35978329
Drug: BI 764524
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 764524 (maximum tolerated dose) in the MD part
Trial: 33441760
Drug: Inland participants
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inland participants (median UIC 188.5 μg/L)
Trial: 33441760
Drug: Coastal participants
RxNorm normalized name: Coastal Water-hyssop Whole
DrugBank: Centella asiatica (DB14256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coastal participants (median UIC 128.5 μg/L)
Trial: 35015777
Drug: Ad26.ZEBOV (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ZEBOV (5 × 10^10 viral particles) and MVA-BN-Filo (1 × 10^8 infectious units) administered 28 or 56 days apart